Showing 1991-2000 of 4941 results for "".
- FDA Approves Olumiant from Eli Lilly for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-olumiant-from-eli-lilly-for-alopecia-areata/2461231/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. FDA action marks the first approval of a systemic treatment for alopecia areata. Olumiant is
- Senté Launches Even Tone Mineral Sunscreenhttps://practicaldermatology.com/news/sente-launches-even-tone-mineral-sunscreen/2461230/Senté has launched Even Tone Mineral Sunscreen. The new tinted sunscreen formulas protect the skin from damage caused by visible light in addition to UV rays and are specifically designed to promote even skin tone in every complexion, the company says.
- Higher Fish Consumption Linked to Melanoma Riskhttps://practicaldermatology.com/news/higher-fish-consumption-linked-to-melanoma-risk/2461229/Eating higher levels of fish, including tuna and non-fried fish, may increase melanoma risk, according to a large study of US adults published in Cancer Causes & Control. When compared to those whose median daily fish intake was 3.2 grams, the risk of malignant melanom
- New Research Reveals Roughly 4 in 5 Acne Sufferers Have Missed Moments in Their Life Due to Acnehttps://practicaldermatology.com/news/new-research-reveals-roughly-4-in-5-acne-sufferers-have-missed-moments-in-their-life-due-to-acne/2461227/Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey released today. The survey was conducted on behalf of Cutera, Inc., which offers AviClear, the first
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- Verrica Receives Complete Response Letter from FDA for NDA for VP-102https://practicaldermatology.com/news/verrica-receives-complete-response-letter-from-fda-for-nda-for-vp-102/2461214/The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc.'s New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). According to the company, the only deficiency listed in the CRL was related to the deficiencies
- Lullage Launches in US on International Skin Pigmentation Dayhttps://practicaldermatology.com/news/lullage-launches-in-us-on-international-skin-pigmentation-day/2461213/Lullage, known as Bella Aurora in Europe and Asia, celebrates International Skin Pigmentation Day to raise awareness about the prevalence of skin pigmentation conditions and the
- Global Dermatology Coalition Launcheshttps://practicaldermatology.com/news/global-dermatology-coalition-launches/2461212/The Global Dermatology Coalition, a patient-led, multi-stakeholder group of organizations, has launched during the 75th World Health Assembly in Geneva. The Global D
- June Risser Named General Manager of Premium Skincare Business Unit at Crown Laboratorieshttps://practicaldermatology.com/news/june-risser-named-general-manager-of-premium-skincare-business-unit-at-crown-laboratories/2461207/June Risser is Crown Laboratories, Inc.’s new General Manager of Premium Skincare. She will lead the global business unit which includes StriVectin and Vita Liberata, and she will hold a position on the Executive Leadership Team. Prior to Crown, she was General Man
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir